In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trek Therapeutics PBC

www.trektx.com

Latest From Trek Therapeutics PBC

Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer

Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.

Research & Development Deals

Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech

Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.

Deals M & A

HCV Patient Access: Trek Therapeutics Takes The Road Less Traveled

Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.

BioPharmaceutical Infectious Diseases

Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Trek Therapeutics PBC
  • Senior Management
  • Ann D Kwong, PhD, CEO
    Michael Bator, CFO
    Kevin J Bittorf, VP, Bus. Dev.
    Robert Hindes, MD, CMO
    Xiao Tong, PhD, VP, Research
  • Contact Info
  • Trek Therapeutics PBC
    Phone: (617) 500-4320
    125 Cambridge Park Dr.
    Ste. 301
    Cambridge, MA 02140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register